Price Alert

OptimizeRx Corporation (OPRX)

NASDAQ: OPRX · Real-Time Price · USD

17.59

0.26 (1.50%)

At close: Aug 14, 2025, 3:59 PM

17.35

-1.36%

After-hours: Aug 14, 2025, 07:54 PM EDT

1.50% (1D)

Bid	14
Market Cap	326.56M
Revenue (ttm)	94.36M
Net Income (ttm)	-15.41M
EPS (ttm)	-0.54
PE Ratio (ttm)	-32.57
Forward PE	26.29
Analyst	Buy

Ask	18.62
Volume	368,744
Avg. Volume (20D)	321,109
Open	17.19
Previous Close	17.33
Day's Range	16.53 - 17.73
52-Week Range	3.78 - 18.22
Beta	1.33

About OPRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol OPRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for OPRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

OptimizeRx has released their quartely earnings on Aug 7, 2025:

Revenue of $29.2M exceeds estimates by $6.89M, with 55.19% YoY growth.

EPS of 0.24 exceeds estimates by 0.27, with 1100.00% YoY growth.

Next Earnings Release

OptimizeRx Corporation is scheduled to release its earnings on Nov 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+34.74%

OptimizeRx shares are trading higher after the com... Unlock content with Pro Subscription

1 week ago

+2.88%

OptimizeRx shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance above estimates.

News

1 week ago · seekingalpha.com

OptimizeRx Corporation (OPRX) Q2 2025 Earnings Call Transcript

OptimizeRx Corporation (NASDAQ:OPRX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Andrew Jacob D'Silva - Senior Vice President of Corporate Finance Edward Stelmakh ...

1 week ago · zacks.com

OptimizeRx Corp. (OPRX) Surpasses Q2 Earnings and Revenue Estimates

OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago.

1 week ago · zacks.com

Best Growth Stocks to Buy for August 7th

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today August 7th:

1 week ago · zacks.com

Best Growth Stocks to Buy for August 5th

Here are three stocks with buy ranks and strong growth characteristics for investors to consider today August 5th:

2 weeks ago · zacks.com

Best Growth Stocks to Buy for August 1st

OPRX, JBL and ADRNY made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 1, 2025.

2 weeks ago · zacks.com

Bull Of The Day: OptimizeRX (OPRX)

This stock is reporting earnings next week and posting positive operating margins is going to be key.

2 weeks ago · zacks.com

Does OptimizeRx Have a Moat in the Crowded HealthTech Space?

OptimizeRx OPRX is carving out a secure niche in the increasingly crowded HealthTech landscape, signaling a developing moat anchored in scale, data and execution. Over the previous two quarters, the ...

3 weeks ago · zacks.com

OPRX Delivers Solid Q1 Earnings: But Can It Sustain the Momentum?

OptimizeRx posts 11% Q1 growth and rising EBITDA, but long-term momentum hinges on scaling subscriptions and margin mix gains.

3 weeks ago · zacks.com

Best Growth Stocks to Buy for July 22nd

OPRX, ADRNY and DELL made it to the Zacks Rank #1 (Strong Buy) growth stocks list on July 22, 2025.

4 weeks ago · seekingalpha.com

OptimizeRx: Stock Could Rise As Profitability Is Achieved

I expect OptimizeRx to turn profitable in 2025, driven by strong double-digit revenue growth and reduced operating expenses. The company's proprietary AI-powered omnichannel platform connects over 2 m...

Load More News